<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655679</url>
  </required_header>
  <id_info>
    <org_study_id>VTP-38543-001</org_study_id>
    <nct_id>NCT02655679</nct_id>
  </id_info>
  <brief_title>An Ascending Multiple Dose Study of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled Ascending Multiple Dose and Clinical Proof-Of-Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitae Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitae Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics,
      pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream,
      twice-daily, for 28 days in otherwise healthy adult male and female patients with mild to
      moderate atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, vehicle-controlled study to evaluate the safety,
      tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of
      VTP-38543 following twice-daily, every twelve hours (Q12h) administration for 28 days in
      otherwise healthy adult male and female patients with mild to moderate atopic dermatitis.
      Evaluation of three ascending doses in three patient panels is planned for this trial. Dose
      Panel 1 and 2 will each enroll 30 patients and randomize 20 to VTP-38543 and 10 to matching
      vehicle control (Vehicle 1). Dose Panel 3 will enroll 40 patients and randomize 20 to
      VTP-38543 and 20 to matching vehicle control (Vehicle 2). A total of approximately 100
      patients will participate in the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment-related AEs listed by subject and summarized by dose and time point</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal laboratory values listed by subject and summarized by dose and time point</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal vital signs listed by subject and summarized by dose and time point</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal ECG values listed by subject and summarized by dose and time point</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) will be summarized using descriptive statistics by visit and dose level</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentrations (tmax) will be summarized using descriptive statistics by visit and dose level</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration (AUCt) will be summarized using descriptive statistics by visit and dose level</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration versus time curve, from time 0 to infinity (by extrapolation) (AUC∞) will be summarized using descriptive statistics by visit and dose level</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t½) will be summarized using descriptive statistics by visit and dose level</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total BSA will be summarized using descriptive statistics by visit and dose level.</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in IGA will be summarized using descriptive statistics by visit and dose level.</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in SCORAD will be summarized using descriptive statistics by visit and dose level.</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline EASI will be summarized using descriptive statistics by visit and dose level.</measure>
    <time_frame>Days 0 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VTP-38543 administered topically every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VTP-38543 administered topically every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VTP-38543 administered topically every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle matching VTP-38543 administered topically every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle matching VTP-38543 administered topically every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VTP-38543</intervention_name>
    <description>VTP-38543 administered topically every 12 hours</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle matching VTP-38543 administered topically every 12 hours</description>
    <arm_group_label>Vehicle 1</arm_group_label>
    <arm_group_label>Vehicle 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate atopic dermatitis with a minimum of 3 to a maximum of 15% body
             surface area (BSA) involvement

          -  IGA score of 2 or 3

          -  BMI = 18 - 35 kg/m2

          -  Medically healthy (exclusive of atopic dermatitis)

          -  Negative Pregnancy test for females

        Exclusion Criteria:

          -  Treatment for atopic dermatitis with systemic medications, topical agents, and
             parenteral biological/monoclonal antibody agents, within specific time period prior to
             dosing.

          -  Organ dysfunction or any clinically significant deviation from normal in VS, PE, labs,
             and ECG findings

          -  ALT, AST or total bilirubin exceeding 1.5x the upper limit of normal at Screening

          -  Major surgery within 3 months of Screening

          -  Use of prescription drugs, sedative antihistamine, medical devices for treatment of
             AD, and topical products containing urea and/or ceramides within 14 prior to dosing

          -  Hemoglobin within 5% of the lower limits of normal

          -  Abnormal aPTT or PT at Screening

          -  Excessive sun exposures, use of tanning booths or other ultraviolet (UV) light sources
             4 weeks prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Gregg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vitae Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dundee Deermatology</name>
      <address>
        <city>West Dundee</city>
        <state>Illinois</state>
        <zip>60118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialty Dermatology</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Company, Inc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirk Barber Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G1B1CA</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratica Medical Inc</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Dermatology / Institution</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research Inc</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Isabelle Delorme Inc</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <zip>J2B 5L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

